CN116196351A - Infant defervescing patch and preparation method and application thereof - Google Patents
Infant defervescing patch and preparation method and application thereof Download PDFInfo
- Publication number
- CN116196351A CN116196351A CN202310166455.XA CN202310166455A CN116196351A CN 116196351 A CN116196351 A CN 116196351A CN 202310166455 A CN202310166455 A CN 202310166455A CN 116196351 A CN116196351 A CN 116196351A
- Authority
- CN
- China
- Prior art keywords
- parts
- infant
- patch
- antipyretic
- defervescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 230000001754 anti-pyretic effect Effects 0.000 claims abstract description 20
- 239000002221 antipyretic Substances 0.000 claims abstract description 18
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 13
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 12
- 235000020224 almond Nutrition 0.000 claims abstract description 12
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 9
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940116229 borneol Drugs 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 7
- 235000013312 flour Nutrition 0.000 claims abstract description 6
- 241000287828 Gallus gallus Species 0.000 claims abstract description 4
- 210000004681 ovum Anatomy 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 5
- 235000014103 egg white Nutrition 0.000 claims description 5
- 210000000969 egg white Anatomy 0.000 claims description 5
- 241000272525 Anas platyrhynchos Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 36
- 206010037660 Pyrexia Diseases 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 20
- 208000002193 Pain Diseases 0.000 abstract description 16
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 31
- 210000004072 lung Anatomy 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 206010011224 Cough Diseases 0.000 description 16
- 238000010926 purge Methods 0.000 description 15
- 210000004243 sweat Anatomy 0.000 description 13
- 230000036760 body temperature Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 9
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 8
- 229940089837 amygdalin Drugs 0.000 description 8
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 8
- 244000111489 Gardenia augusta Species 0.000 description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- 229960001680 ibuprofen Drugs 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 6
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010013954 Dysphoria Diseases 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000003516 pericardium Anatomy 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 235000018958 Gardenia augusta Nutrition 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 240000005809 Prunus persica Species 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 206010040925 Skin striae Diseases 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000003907 antipyretic analgesic agent Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000013875 Heart injury Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000827125 Lupinus flavoculatus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000411545 Punargentus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- -1 analgesic Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a pediatric defervescence patch, a preparation method and application thereof, wherein the pediatric defervescence patch comprises the following components in parts by mass: 2-5 parts of raw gardenia, 1-3 parts of peach kernel, 1-3 parts of almond and 1-2 parts of borneol. The infant antipyretic patch comprises the following steps: mixing fructus Gardeniae, semen Persicae, semen Armeniacae amarum, and Borneolum Syntheticum, sieving with 80 mesh sieve, pulverizing to obtain fine powder mixture, adding flour and ovum gallus Domesticus album, stirring, and mixing to obtain cake. The application method of the infant antipyretic patch comprises the following steps: the infant antipyretic is applied to the acupoint of Taiyuan, daling and Shenmen of the patient, and is fixed with medicinal gauze for 24 hr. The infantile defervescence patch is prepared by matching with the traditional Chinese medicine to treat infantile exogenous fever in vitro, has the advantages of rapid defervescence, safe administration, short treatment period, no pain, simplicity, easy learning, convenient popularization and easy acceptance by families and children.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pediatric defervescence patch, a preparation method and application thereof.
Background
The temperature regulation point of the heating regulation center of the hypothalamic pre-vision area of the infant is increased to a higher level from the original temperature of 37+/-1 ℃. Exogenous fever is mainly manifested by aversion to cold, fever, cough, nasal obstruction and nasal discharge, and is seen in winter and spring Ji Duo all the year round. The clinical symptoms of the disease are high fever higher than 38.5 ℃, acute onset, rapid change and heavy heat potential, and the disease is one of common emergency symptoms of internal medicine, and is mostly seen in western medicine of acute upper respiratory tract infection. Such emergency is liable to cause dehydration, if the fever is not timely, the emergency can develop into ultrahigh heat, and even can develop into nervous system diseases such as cerebral hemorrhage, viral encephalitis and heat-jet disease, and the like, thus endangering life.
Generally, the temperature below 38.5 ℃ belongs to low fever, and physical cooling is the most scientific, or the main aspects of drinking water and rest are that much water is taken. If the temperature exceeds 38.5 ℃, the antipyretic analgesic drug, the antibiotic or the antiviral drug is taken for treatment by the drug. However, excessive use of antibiotics tends to produce resistance, reduce the sensitivity of the patient to the drug, and the vicious circle is produced thereby. The existing clinical abuse phenomenon of antibiotics is more serious, and toxic and side effects such as liver and kidney function damage, gastrointestinal tract reaction, anaphylactic reaction and the like are unavoidable. Antipyretic analgesic drugs have obvious and quick effects of treating exogenous fever, but have long-lasting effects and are not easy to produce side effects, such as adverse reactions of stimulating gastrointestinal tract to induce peptic ulcer to produce bleeding, producing excessive sweating and the like. The misuse of antipyretic analgesic drugs is frequent, and the drug resistance caused by the misuse is visible everywhere, and even if a part of patients take the maximum dose, the patients still cannot effectively control the body temperature and the body temperature is easy to rise again after defervescence.
The traditional Chinese medicine therapy has numerous methods for treating exogenous fever, rapid fever abatement, definite curative effect, simple operation and no adverse reaction, and is widely applied to clinic. The traditional Chinese medicine has internal treatment and external treatment methods for treating exogenous fever, and has good effects according to clinical reports. The acupoint application therapy is a long-standing source, and as early as the original society, a method for reducing bleeding and pain by using grass stems, leaves and other external wounds is provided, and the method has a mature understanding from the 'shi jiao' of Qing dynasty Wu Shiji: cutting into skin, sucking into meat, and mixing into exudation. The acupoint application therapy is mainly realized by dredging channels and collaterals, harmonizing ying and wei, detoxifying and clearing heat, regulating yin and yang, eliminating evil and strengthening body resistance, and the like, and is equivalent to multiple treatment effects of accelerating metabolism, promoting blood circulation, resisting inflammation and virus, relieving exterior syndrome and bringing down fever, and the like in modern medicine.
Therefore, the Chinese medicinal composition has the advantages of quick defervescence, safe administration, short treatment period, no pain, simplicity, easiness in learning, convenience in popularization and easiness in acceptance by families and children.
Disclosure of Invention
The technical problems to be solved are as follows: aiming at the defects and shortcomings of the prior art, the invention provides the infant defervescence patch and the preparation method thereof, wherein the defervescence patch is prepared by matching an acupoint with a traditional Chinese medicine to externally apply and treat exogenous fever of infants, and has the advantages of rapid defervescence, safe administration, short treatment period, no pain, simplicity, easy learning, convenient popularization and easy acceptance by families and children.
The technical scheme is as follows: an antipyretic patch for children comprises the following components in mass percent: 2-5 parts of raw gardenia, 1-3 parts of peach kernel, 1-3 parts of almond and 1-2 parts of borneol.
The infant antipyretic patch comprises the following components in parts by mass: 4 parts of raw gardenia, 2 parts of peach kernel, 2 parts of almond and 1 part of borneol.
The preparation method of the infant antipyretic patch comprises the following steps of: mixing fructus Gardeniae, semen Persicae, semen Armeniacae amarum, and Borneolum Syntheticum, sieving with 80 mesh sieve, pulverizing to obtain fine powder mixture, adding flour and ovum gallus Domesticus album, stirring, and mixing to obtain patch.
10g of flour and 10mL of duck egg white are added to each 50g of the fine powder mixture.
The application of the infant antipyretic patch is provided.
The application method of the infant antipyretic patch comprises the following steps: the infant antipyretic is applied to the acupoint of Taiyuan, daling and Shenmen of the infant, and is fixed with medicinal gauze for 24 hr.
Among the traditional Chinese medicines in the formula:
gardenia jasminoides ellis: bitter and cold in nature. It enters heart, liver, lung, stomach and triple energizer meridians. Purging fire to relieve restlessness, clearing heat and promoting diuresis, cooling blood and removing toxicity, promoting qi circulation to purge fire, relieving upward, purging lung fire, relieving exterior heat, and relieving exterior heat when exogenous febrile disease and exterior and interior heat exist; it can also dispel triple energizer fire and cool blood and heart heat, and can be used for treating febrile disease with dysphoria: bleeding due to blood heat and stranguria due to heat.
Modern pharmacology of gardenia: has antiinflammatory, cholagogic, antipyretic, analgesic, antioxidant, diuretic, antitumor, radioprotective, and blood lipid reducing effects. The fructus gardeniae has the strongest antipyretic effect on antipyresis and anti-inflammatory effects, has good antipyretic effect on rat fever caused by taking 15% fresh yeast suspension as a heating agent, has a certain sedative effect, and can obviously prolong the influence of sodium isobarbiturate on the sleeping time of mice.
Peach kernel: bitter in flavor, sweet in flavor, flat in nature, qi-balancing and descending, bitter in flavor and purging, with little toxicity. It enters heart, liver, lung and large intestine meridians. Promoting blood circulation, removing blood stasis, relieving stagnation blood, and removing heat in blood; relieving cough and asthma; the fatty oil in peach kernel has the effects of relaxing bowel, lubricating intestinal tracts and facilitating defecation.
Modern pharmacology of peach kernel: amygdalin is one of the active ingredients of peach kernel, is nontoxic per se, but hydrocyanic acid generated after decomposition of amygdalin in peach kernel itself or intestinal flora is extremely toxic, and is the main ingredient causing toxic and side effects of peach kernel, so that oral administration has the greatest toxicity compared with other administration routes. Aiming at the condition of low immunity, the peach kernel protein can improve the humoral immunity function of the organism, promote the generation of antibody forming cells and the generation of serum hemolysin, and correct CD4 + /CD8 + Unbalanced cell ratio, promoting secretion of IL-2 and IL-4, stimulating immunity, correcting disorder, and inhibiting organism inflammatory reaction.
And (3) almond: bitter in property, slightly warm, with small toxicity, enter lung and large intestine meridians. The Chinese medicinal composition has effects of relieving cough, relieving asthma, constipation, and constipation, relieving sore throat, resolving phlegm, promoting the circulation of qi, and dredging meridian.
Modern pharmacology of almonds: the almond mainly contains amygdalin, fatty oil, protein and the like, and the amygdalin has the effects of relieving cough and eliminating phlegm, reducing blood sugar, reducing blood fat, resisting inflammation, resisting ulcer, resisting pulmonary fibrosis, resisting high-oxygen induced lung injury, inhibiting immunity, regulating immunity and the like, and has rich content of the amygdalin oil, and the functions of relieving cough and asthma, relaxing bowel, resisting tumor, expelling parasites and sterilizing. The amygdalin is decomposed into hydrocyanic acid and benzoic acid under the action of beta-glucosidase in vivo, and the hydrocyanic acid has a certain inhibition effect on respiratory centers, so that the effects of relieving cough and asthma are achieved. Also, studies have shown that amygdalin affects the proliferation of alveolar type II cells and the expression of surface active Substance Protein (SP) mRNA in high-oxygen-exposed premature rats, suggesting that amygdalin in a proper dosage form may be an effective drug for preventing and treating bronchopulmonary dysplasia.
Borneol: pungent and bitter taste, slight cold, heart, spleen and lung meridians, and has the actions of inducing resuscitation, clearing heat and relieving pain, etc., and can "unblock orifices, dispel stagnated fire".
Modern pharmacology of borneol: the borneol is clinically used for treating burns and scalds, eye diseases, apoplexy and other diseases, and has the compatibility of bacteriostasis, antioxidation, pain relieving and inflammation diminishing, antipyretic, cardiovascular and cerebrovascular protection and central nerve protection, and the drug absorption is promoted mainly by increasing the permeability of the blood brain barrier, improving the concentration of the drug in blood, promoting the transdermal absorption and other modes, so that the bioavailability of other drugs is improved, and the aim of enhancing the treatment effect is fulfilled.
Duck egg white: sweet in nature, cool in nature, enters lung and large intestine meridians, and has the effects of nourishing yin, clearing lung-heat, calming liver, relieving diarrhea and the like. Heat in the chest and diaphragm; headache and dizziness caused by liver fire; sore throat; tooth pain; cough; diarrhea and dysentery. Medicine codification: "tonify heart, clear lung, relieve cough with fever, treat sore throat and odontalgia; the decoction is effective for clearing lung-heat, and relieving yang and heat. "
The method of the invention comprises the following steps:
fructus Gardeniae in the recipe can purge fire by moving qi and dispersing, and can purge triple energizer fire, purge lung fire, purge heart heat, remove exterior and interior heat, relieve exogenous exterior and interior heat, purge fire and remove heat from triple meridians of heart and lung. Peach kernel has the effects of promoting blood circulation, removing blood stasis and relaxing bowel; almond relieves cough and dyspnea, moistens intestine and relieves constipation, and both herbs purge heat from lung and large intestine meridians. Egg white nourishes yin and clears away lung heat, and clears away heat from the lung and large intestine channels. The four medicines are combined to clear heart fire, relieve restlessness, cool blood and activate blood, and are effective for treating hyperpyrexia, convulsion and dysphoria.
The three acupuncture points of the antipyretic patch of the invention are as follows:
too much: the lung meridian acupoints of taiyin [ genus ] are the acupoints; original point; the eight points will be referred to as the pulse. On the transverse carpal vein, the acupoint is selected from the radial depression of the radial artery. The main indications are asthma, cough, hemoptysis, dry throat, sore throat, pain in the basin, pain in the chest, pain in the inner side of the upper arm; no pulse condition exists.
The mausoleum: the pericardium meridian acupoints of hand jueyin [ genus ] are the acupoints; original point. In the anterior wrist region, in the distal transverse carpal-palmar vein, there is a space between the longus palmaris tendon and the flexor carpi radialis tendon. [ mainly used ] cardiodynia, palpitation; stomach ache and vomiting; chest and hypochondrium distending pain; smiling, sad, manic epilepsy; arm and hand contracture pain.
The door is: the acupoints on the heart meridian of hand taiyin [ genus ] are the acupoints; original point. In the anterior wrist region, the distal carpometacarpal lateral end, the radial margin of the ulnar flexor carpus tendon. [ mainly used for treating heart pain, palpitation and severe palpitation; vexation, amnesia, insomnia, dementia, mania; hypertension; chest and hypochondrium pain.
And (5) hole selection analysis: taiyuan, daling, shenmen are the points of the meridians and the original points, ling Pi-evil qi cangfu Bing Zhong (Ling Pi-Xie Shen Fu Bing Zhong): the spring points are used for treating the external meridians, it is combined with interior. The spring points are used for treating peripheral diseases of meridians, while the combination points are used for treating visceral diseases, the original points are the points where the original qi of viscera passes through and is retained, and the original points of yin meridians are the points of five meridians. The three points have the functions of both the infusion and the original points. The original points are used clinically to activate the original qi by making the triple energizer pass through, and to regulate the healthy qi in the body to resist pathogenic factors, mainly for regulating the deficiency and excess pathological changes of viscera, meridians.
The lung is in the body and in the hair, and because the lung and the hair are in the body and in the hair, the lung is often affected when the external evil invades the hair, the knee is in obstruction, and the defensive qi is stagnated, so that the lung qi is not dispersed; pathogenic factors invade the lung and when lung qi is not dispersed, it can cause pathological changes such as knee obstruction and qi stagnation. In traditional Chinese medicine, sweat pores are called as 'valves', namely sweat pores not only excrete sweat formed by body fluid, but also exchange gas in and out of the body along with the dispersion and descending of lung, so Tang-Cheng Chuan indicates in Yi Jingjing Yi, and fur also has the effect of 'benefiting lung qi'. In the theory of meridians, the lung meridian conditions of hand taiyin are: "is the patient with the main lung. Cough, dyspnea and thirst, dysphoria, chest fullness, pain and syncope in the arm, and heat in the palm. "
Sweat is the liquid that is discharged from the Xuanfu (sweat pores) after body fluid is transformed by the transpiration of yang qi. So the theory of "Su Wen-Yi Yang Bien": "yang is added to yin to mean sweat". Wu "epidemic febrile disease strip" in: the sweat also manifests as the pattern of yang, qi and yin being steamed. "sweat excretion, also depends on the action of Yu Wei on the opening and closing of the striae: sweat is excreted when the striae are opened; the striae are closed, and there is no sweat. Since sweat is produced by body fluids, blood and body fluids are the same source, so there is a theory of "sweat and blood homology". Blood is the heart, so it is called "sweat is the heart liquid". In the theory of meridians, the disorders of the heart meridian of hand shaoyin are: is a patient with yellow eyes, hypochondriac pain, pain in the arm, syncope and heat in the palm. "
The pericardium, called pericardium for short, is the envelope that wraps the outside of the heart, and has the function of protecting the heart. In the theory of visceral manifestation, the envelope of the heart is considered to be the periphery of the heart and has the effect of protecting the heart, so exogenous pathogens attack the heart, and first, the envelope is affected. The 'ling frame and evil guest' is that: the heart is the major part of the five zang-organs and six fu-organs, the spirit is the same as the viscera's perpendicular and round, and the pathogenic factors can be kept. The heart injury is usually the condition that the heart injury is the condition that the mind is removed and the condition that the mind is removed is the condition that the mind is dead. Therefore, all pathogens lie in the heart and are all located in the envelope of the heart. Therefore, in the theory of warm diseases, the symptoms such as coma and delirium occurring in exogenous febrile disease are called "heat entering the pericardium" or "shielding the pericardium". In the theory of meridians, the hand jueyin meridian belongs to the heart envelope, and the symptoms of the hand jueyin heart envelope are as follows: the patients with the disease of the main pulse are dysphoria, heart pain and heat in the palms. "
The invention mainly achieves the aim of treating exogenous fever of children by removing heat evil of heart, lung and triple energizer and clearing Jin Tuire.
The invention has the following indications: can be used for treating fever caused by exogenous pathogenic factors.
The invention has the following contraindications: the invention is externally applied with allergy history.
The traditional Chinese medicine prescription of the invention comprises the following dosage and method: the traditional Chinese medicine patch is taken as a dose, and is replaced every 24 hours. During the application of the acupoint plaster, the patient should pay attention to: the cause of fever is eliminated, and fever caused by non-exogenous factors is eliminated.
The beneficial effects are that: the infant antipyretic patch provided by the invention and the preparation method and application thereof have the following beneficial effects:
1. the defervescence patch is rapid in defervescence, safe in medication, short in treatment period, painless, simple and easy to learn, convenient to popularize and easy to accept by families and children;
2. in the formula of the invention, cape jasmine is a monarch drug for purging fire by moving qi and separating, and is capable of clearing ascending, purging triple energizer fire, purging lung fire, clearing heart heat, removing exterior heat of muscles, relieving exterior heat of exogenous pathogenic factors, and purging fire and removing heat from triple meridians of heart and lung. Peach kernel is used as ministerial drug for promoting blood circulation, removing blood stasis and relaxing bowel; almond is an adjuvant drug for relieving cough and asthma, loosening bowel to relieve constipation, and both herbs purge heat from the lung and large intestine meridians. Egg white is used as an guiding drug for nourishing yin and clearing lung-heat, and clearing away heat from the lung and large intestine channels. The four medicines are combined to clear heart fire, relieve restlessness, cool blood and activate blood, and are effective for high fever, convulsion and dysphoria, and the medicines are also daily, simple and easy to operate.
Detailed Description
The above-described aspects of the present invention will be described in further detail below by way of specific embodiments of the present invention. It should not be construed that the scope of the above subject matter of the present invention is limited to the following examples. Various substitutions and alterations are also possible, without departing from the spirit of the invention, and are intended to be within the scope of the invention.
Example 1
The embodiment provides a fever reducing patch for children, wherein the prescription comprises the following components in parts by weight: 20g of raw gardenia, 15g of peach kernel, 10g of almond and 5g of borneol.
The preparation method comprises the following steps: mixing fructus Gardeniae, semen Persicae, semen Armeniacae amarum, and Borneolum Syntheticum, sieving with 80 mesh sieve, pulverizing to obtain fine powder mixture, adding 10g flour and 10mL ovum gallus Domesticus album into the fine powder mixture, stirring, and mixing to obtain cake-like patch.
The using method is as follows: the preparation method comprises applying the antipyretic plaster to the acupoint of the infant's Taiyuan, daling, and Shenmen, fixing with medicinal gauze, and replacing once for 24 hr.
Clinical efficacy observation is carried out on the infant defervescing patch prepared in the example 1: clinical observations were made on 48 cases of exogenous fever of children in the national medical hall of the university of Nanjing traditional Chinese medicine at time 2018.09-2019.03.
Inclusion criteria: (1) Reference to the 7 th edition of practical science, meets the diagnosis standard of acute upper respiratory tract infection and leads to fever; (2) the fever course is within 72 hours; (3) After the illness, the body temperature is more than or equal to 38.5 ℃ (the temperature of an armpit mercury thermometer); (4) age: 6 months to 5 years old; (5) No ibuprofen is orally taken and external allergies such as cape jasmine, peach kernel, almond, camphor and the like are caused.
Exclusion criteria: (1) Fever of non-acute upper respiratory tract infection and unknown cause; (2) infants suffering from acute suppurative tonsillitis and nasosinusitis; (3) Patients with serious systemic diseases such as cardiovascular diseases, liver diseases, renal diseases, hematopoietic diseases, etc., and allergic diseases to the drug; (4) those with significant abnormalities in heart rate and respiratory rate; (5) If the medicine is not taken continuously, the medicine is changed or added in the middle of the medicine, and the curative effect cannot be judged.
The treatment method comprises the following steps: the western medicine symptomatic treatments of the two groups of children patients are the same, such as those accompanied by convulsions and coughs, and the treatment of sedation and cough is given. On the basis, when the body temperature exceeds 38.5 ℃ (the temperature of an armpit mercury thermometer), the ibuprofen suspension drop is added for oral administration, and the ibuprofen suspension drop can be repeatedly used every 6-8 hours if necessary, and the ibuprofen suspension drop can be used every 24 hours for not more than 4 times, and is 5-10 mg/kg each time. The treatment group (ibuprofen+the present invention) was a course of treatment for 3 days based on the above-described symptomatic western medicine treatment and ibuprofen suspension drops orally.
Standard of efficacy: (1) heating: and (3) judging by referring to the standard established by the clinical guidelines for exogenous fever of children in the Chinese medicine New drug clinical guidelines issued by the Ministry of health of the Chinese people's republic of China in 1993. And (3) curing: the body temperature is recovered to be normal (the armpit detection of the thermometer is reduced to below 37 ℃ and the armpit detection is not raised any more) after the medicine is taken for 24 to 48 hours; the method is effective: the body temperature is recovered to be normal after 48 to 72 hours of medication; invalidation: within 72 hours of administration, body temperature did not improve.
Analysis of results: 29 cases of treatment groups are cured, 7 cases are effective, 2 cases are ineffective, and the total effective rate is 93.10%; the control group of 28 cases is cured by 15 cases, 8 cases are effective, 5 cases are ineffective, and the total effective rate is 82.14%.
The total effective rate of the treatment group after the treatment of the treatment group by the embodiment is 93.10 percent on the basis of Western medicine, which is obviously higher than 82.14 percent of that of the control group, and the difference between the two has statistical significance (P is less than 0.05). By comparing the data of the treatment group with the data of the control group, the invention has remarkable advantages in treating the exogenous fever of children.
| Cure (personal) | Effective (personal) | Invalidation (personal) | Total effective rate (%) | |
| Treatment group | 20 | 7 | 2 | 93.10 |
| Control group | 15 | 8 | 5 | 82.14 |
Typical cases:
case 1: cheng Mou, 3.6 years old, 2015, 10 months and 9 days of initial diagnosis. The infant has fever for 1 day (Tmax39.9deg.C), with cough, nasal discharge, abdominal distention, dry stool, and palm heat after 2 days; the infant is suffering from pharyngeal congestion, tonsil inflammation, I degree swelling, rice-like follicular, red tongue with yellow coating, and superficial and rapid pulse. Diagnosis: heating. The infant tuina and defervescing plaster are externally applied for 3 days to defervesce.
Case 2: chen Mou when a man is in the age of 3 years and visits in 2018 in 10 months, the infant has no obvious cause of fever in 1 day before the visit, the body temperature is up to 39 ℃, the infant is treated by taking ibuprofen suspension and isatis root granules at home, the body temperature is temporarily reduced, but the infant rises again after a few hours. The body temperature is 39.2 ℃, the nasal discharge is caused, the throat pain is relieved, the cough is relieved, the diet is poor, and the stool is dry. Checking: the pharynx is engorged with blood, the tonsils are enlarged in degree I, and the heart and lung are not abnormal. Diagnosis: exogenous fever. The infant tuina and defervescing patch is externally applied for 2 days to defervesce.
The embodiments of the present invention have been described in detail in the above examples, but the present invention is not limited to the above embodiments, and various changes may be made without departing from the spirit of the present invention within the knowledge of one of ordinary skill in the art. The above description is only of the preferred embodiments of the present invention, and is not intended to limit the scope of the claims, but all equivalent structural changes made by the application of the present invention are included in the scope of the claims.
Claims (6)
1. The infant antipyretic patch is characterized by comprising the following components in parts by mass: 2-5 parts of raw gardenia, 1-3 parts of peach kernel, 1-3 parts of almond and 1-2 parts of borneol.
2. The infant antipyretic patch according to claim 1, which is characterized by comprising the following components in mass: 4 parts of raw gardenia, 2 parts of peach kernel, 2 parts of almond and 1 part of borneol.
3. The method for preparing the infant antipyretic patch according to any one of claims 1 to 2, characterized by comprising the steps of: mixing fructus Gardeniae, semen Persicae, semen Armeniacae amarum, and Borneolum Syntheticum, sieving with 80 mesh sieve, pulverizing to obtain fine powder mixture, adding flour and ovum gallus Domesticus album, stirring, and mixing to obtain patch.
4. A method for preparing a pediatric defervescing patch according to claim 3, wherein: 10g flour and 10mL duck egg white were added to each 50g of the fine powder mixture.
5. Use of a pediatric defervescing patch according to any one of claims 1-2.
6. The use of a pediatric defervescing patch according to claim 5, characterized by the following method: the infant antipyretic is applied to the acupoint of Taiyuan, daling and Shenmen of the infant, and is fixed with medicinal gauze for 24 hr.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310166455.XA CN116196351A (en) | 2023-02-27 | 2023-02-27 | Infant defervescing patch and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310166455.XA CN116196351A (en) | 2023-02-27 | 2023-02-27 | Infant defervescing patch and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116196351A true CN116196351A (en) | 2023-06-02 |
Family
ID=86510862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310166455.XA Pending CN116196351A (en) | 2023-02-27 | 2023-02-27 | Infant defervescing patch and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116196351A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102327349A (en) * | 2011-09-23 | 2012-01-25 | 蔡敏泽 | Infant quick-acting antipyretic powder |
| CN104115129A (en) * | 2011-12-21 | 2014-10-22 | 英特尔公司 | System and method for intelligently flushing data from a processor into a memory subsystem |
-
2023
- 2023-02-27 CN CN202310166455.XA patent/CN116196351A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102327349A (en) * | 2011-09-23 | 2012-01-25 | 蔡敏泽 | Infant quick-acting antipyretic powder |
| CN104115129A (en) * | 2011-12-21 | 2014-10-22 | 英特尔公司 | System and method for intelligently flushing data from a processor into a memory subsystem |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104147284B (en) | Chinese herbal preparation for treating epilepsy and preparation method thereof | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| TW202406564A (en) | A chinese medicinal composition and its application | |
| CN115300544B (en) | Traditional Chinese medicine composition and patch for dispelling wind, relieving exterior syndrome, detumescence and inducing resuscitation and preparation method thereof | |
| CN116196351A (en) | Infant defervescing patch and preparation method and application thereof | |
| CN114796325A (en) | Traditional Chinese medicine composition for treating knee osteoarthritis and preparation method and application thereof | |
| CN101181448A (en) | Oral administration proprietary Chinese medicine for curing facial palsy | |
| CN1058612C (en) | Bixiling ointment and preparation thereof | |
| CN117414351B (en) | Traditional Chinese medicine patch for treating spleen-kidney yang deficiency constipation and preparation method and application thereof | |
| CN108686186A (en) | A kind of navel paster for treating allergic rhinitis | |
| CN114504635B (en) | Chinese patent medicine for treating apoplexy sequela | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN110787237B (en) | Traditional Chinese medicine composition for effectively treating gastrocnemius spasm and preparation method and application thereof | |
| CN114042109B (en) | Traditional Chinese medicine composition and patch for inducing resuscitation and stopping nasal discharge, warming yang and strengthening body resistance and preparation method | |
| CN115531513B (en) | Traditional Chinese medicine preparation for treating adult snoring and preparation method thereof | |
| CN105125973A (en) | Traditional Chinese medicine preparation for treating infantile bronchitis | |
| CN118512570A (en) | Traditional Chinese medicine composition for treating epigastric pain, external application patch and application thereof | |
| CN117427127A (en) | Traditional Chinese medicine composition for treating peripheral arthralgia | |
| CN117919363A (en) | Traditional Chinese medicine composition for treating sleep disorder | |
| CN1060662C (en) | Foot-washing antitussive lotion and its preparing method | |
| CN114848788A (en) | Cortex lycii radicis powder decoction as well as preparation method and application thereof | |
| CN118217340A (en) | Pharmaceutical composition for treating 0-grade diabetic foot and self-heating medication sleeve thereof | |
| CN112891425A (en) | Traditional Chinese medicine composition for ascending the clear, descending the turbid and benefiting the spleen | |
| CN111632112A (en) | Wind-calming and collateral-dredging preparation and preparation method thereof | |
| CN116549520A (en) | Qi-blood tonifying, lung heat clearing and cough relieving traditional Chinese medicine formula, traditional Chinese medicine liquid and traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |